Acute myeloid leukemia (AML) is an urgent unmet need. Of the estimated 20,800 cases in the U.S. in 2024, 11,220 resulted in deaths. Less than 50 percent of patients with AML are eligible for intensive chemotherapy, and all patients will relapse.
Relapsed/refractory AML (R/R AML) refers to the condition in which a patient does not achieve complete remission after two cycles of induction chemotherapy, and the response rate of available treatments is approximately 15 percent. With no defined standard of care, except for a few patients with genetic mutations, the time required to identify genetic results may impede crucial clinical decisions.
AML is one of the deadliest leukemias and is the most common acute leukemia in adults. Globally, the annual number of newly diagnosed patients of all leukemias has increased by 46 percent in the past three decades, with AML having increased by 15 percent. Outcomes are worst in the subset of patients who are aged 65 years, in which only 30 percent survive at one-year intervals.
